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Tumors depend on their microenvironment for sustained
growth, invasion, andmetastasis. In this environment, endothe-
lial cells (ECs) are an important stromal cell type interacting
withmalignant cells to facilitate tumor angiogenesis and cancer
cell extravasation. Of note, lysosomal acid lipase (LAL) defi-
ciency facilitates melanoma growth and metastasis. ECs from
LAL-deficient (lal/) mice possess enhanced proliferation,
migration, and permeability of inflammatory cells by activating
the mammalian target of rapamycin (mTOR) pathway. Here we
report that lal/ ECs facilitated in vivo tumor angiogenesis,
growth, andmetastasis, largely by stimulating tumor cell prolif-
eration, migration, adhesion, and transendothelial migration
via increased expression of IL-6 andmonocyte chemoattractant
protein 1 (MCP-1). This prompted us to look for lysosomal pro-
teins that are involved in lal/ EC dysfunctions.We found that
lal/ ECs displayed increased expression of Rab7, a late endo-
some/lysosome-associated small GTPase. Moreover, Rab7 and
mTOR were co-increased and co-localized to lysosomes and
physically interacted in lal/ ECs. Rab7 inhibition reversed
lal/ EC dysfunctions, including decreasing their enhancedmi-
gration and permeability of tumor-stimulatory myeloid cells,
and suppressed EC-mediated stimulation of in vitro tumor cell
transmigration, proliferation, and migration and in vivo tumor
growth and metastasis. Finally, Rab7 inhibition reduced over-
production of reactive oxygen species and increased IL-6 and
MCP-1 secretion in lal/ ECs. Our results indicate that meta-
bolic reprogramming resulting from LAL deficiency enhances
the ability of ECs to stimulate tumor cell proliferation and
metastasis through stimulation of lysosome-anchored Rab7
activity.
Tumorigenesis is a complex process during which tumors
depend on the microenvironment for sustained growth, inva-
sion, and metastasis (1). Endothelial cells (ECs)3 are one of the
important stromal cell types within the tumor microenviron-
ment that have a strong influence on tumor cells and tumor-
associated immune cells. ECs regulate tumor proliferation and
progression in several ways. First, ECs participate in tumor
angiogenesis by forming tumor vasculature, which provides
tumor cells with oxygen and nutrients to satisfy their growing
need (2). It has already been reported that cross-talk between
tumors and ECs promotes tumor angiogenesis (3). Second, ECs
interact with cancer cells, affecting the efficiency of cancer cell
migration and extravasation (4). Third, ECs influence tumor
proliferation and progression by regulating immune cells (5).
For example, ECs isolated from tumor tissue are able to inhibit
T cell functions (6). To effectively limit the contributions of ECs
to tumor proliferation and progression, it is necessary to block
the pathogenic influence of ECs on tumor cells.
The angiogenic switch of ECs in tumor proliferation and pro-
gression is metabolically demanding and mediated by adapta-
tions in EC metabolism (7). Emerging evidence indicates that
the metabolic change determines not only EC differentiation
and angiogenesis but also the pathogenic functions of ECs in
cancer (8). We have demonstrated that metabolic reprogram-
ming during deficiency of lysosomal acid lipase (LAL) increases
EC proliferation, migration, and the permeability of tumor-
promotingmyeloid-derived suppressor cells (MDSCs) and sup-
pression of T cell proliferation and functions (9). LAL is a key
enzyme in the metabolic pathway of neutral lipids that hydro-
lyzes cholesteryl esters and triglycerides in the lysosome of cells
to generate free fatty acids and cholesterol (10, 11). Metabolic
switch of LAL deficiency in ECs induces overactivation of the
mammalian target of rapamycin (mTOR) pathway, which is a
lysosome-anchored metabolic regulator and mediates lal/
EC dysfunction (9). LAL is a lysosome-localized enzyme that
influences endomembrane trafficking and mTOR shuttling to
lysosomes (12, 13).While searching for lysosomal proteins that
are involved in LAL and mTOR activities, Rab7 GTPase was
found to be up-regulated in lal/ ECs, similar to what was
observed in lal/ MDSCs (14). Rab7 GTPase has been
reported to be a key regulatory protein for proper aggregation
and fusion of late endocytic structures in the perinuclear region
and consequently for the biogenesis and maintenance of the
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lysosomal compartment in cells (15, 16). We further identified
that Rab7 GTPase was co-localized with mTOR and lysosomes
in lal/ ECs and physically interacted with mTOR to influ-
ence its downstream signaling. In this study, we focused on how
Rab7 GTPase in lal/ ECs affects their stimulation of tumor
proliferation, growth, and metastasis. These findings provide
mechanistic insight into LAL deficiency facilitating metastasis
and indicate a potential target on ECs for anti-tumor therapy.
Results
ECs with LAL deficiency stimulated tumor angiogenesis,
growth, andmetastasis
Angiogenesis is essential for tumor growth and metastasis,
during which ECs and tumor cells interact to facilitate the for-
mation of new blood vessels. To see whether LAL deficiency
plays a role in EC stimulation of tumor angiogenesis, an in vivo
Matrigel plug assay was performed with wild-type (lal/) or
lal/ ECs mixed with tumor cells. The mixture was subcuta-
neously injected into lal/ recipient mice for a tumor angio-
genesis and growth study. Ten days post-injection, the plugs
were harvested, sectioned, and stained with H&E. Plugs mixed
with lal/ ECs and B16 melanoma cells had a larger size and
heavier weight than those mixed with lal/ ECs and B16 mel-
anoma cells (Fig. 1, A–C). Consistently, H&E staining revealed
robust melanoma cell proliferation in plugs containing lal/
ECs (Fig. 1D) and more newly formed microvessels in plugs
containing lal/ ECs than in those with lal/ ECs (Fig. 1D,
arrows). Similar results were observed when ECs were mixed
with Lewis lung carcinoma (LLC) cells (Fig. 1, A–D).
Next, lal/ or lal/ ECs mixed with B16 melanoma cells
were co-injected into the tail veins of lal/ recipient mice to
detect the potential effect of ECs on tumor cell invasion. Two
weeks after injection, compared with mice that received lal/
ECs and melanoma cells, mice co-injected with lal/ ECs and
melanoma cells developed more melanoma colonies in the
lungs (Fig. 1E). H&E staining revealed more neoplastic mela-
noma cells in lungs that received lal/ ECs than in those that
received lal/ ECs (Fig. 1F). A similar stimulation of meta-
static invasion was observed when lal/ ECs were co-injected
with LLC cells into lal/ recipient mice, with more neoplastic
cells in lungs that received lal/ ECs (Fig. 1, E and F). Taken
together, ECs with LAL deficiency stimulated tumor angiogen-
esis, growth, and metastasis.
ECs with LAL deficiency stimulated tumor cell proliferation,
migration, adhesion, and transendothelial migration
The stimulatory effects of lal/ ECs on tumor growth and
invasion were further examined by in vitro experiments. To
evaluate the influence of lal/ECs on tumor cell proliferation,
tumor cells were treated with lal/ or lal/ EC-conditioned
medium (CM) for 72 h. As shown in Fig. 2A, compared with
lal/ EC-CM treatment, lal/ EC-CM treatment signifi-
cantly increased the proliferationof B16melanomaandLLCcells.
Attachment of cancer cells to ECs is the first step of the extravasa-
tion process (4). Therefore, whether LAL deficiency in ECs affects
tumor cell attachment was examined. CellTrackerTM Green
5-chloromethylfluorescein diacetate (CMFDA)–labeled tumor
cells (B16 melanoma or LLC cells) were added to the EC
monolayer and incubated for 3 h. As Fig. 2B shows, both B16
melanoma andLLCcells showed significantlymore adhesion to
lal/ ECs compared with lal/ ECs. After attachment to
ECs, tumor cells transmigrate through EC junctions. A Tran-
swell assay was performed to determine tumor cell transmigra-
tion across the endothelial monolayers formed by lal/ or
lal/ ECs. ECs were seeded into Transwell upper chambers
and grown to confluence. CMFDA-labeled LLC cells were
loaded on the ECmonolayers. Fifteen hours later, the LLC cells
that hadmigrated to the lower chamberwere counted. Consist-
ent with their higher adhesion to tumor cells, lal/ ECs
showed increased permeability, with more LLC cells migrating
to the lower chamber than lal/ ECs (Fig. 2C). Our pioneer
study showed that transmigrated B16 cells across the endothe-
lial monolayer tightly attached to the membrane of the inserts
and did not migrate to the bottom of the chamber. In addition,
an in vitro tumor cell migration assay was performed to deter-
mine whether lal/ ECs influence tumor cell migration.
Figure 1. lal/ ECs stimulated tumor angiogenesis, growth, andmetas-
tasis in vivo.A, B16melanomaor LLCcells (1105)weremixedwith lal/or
lal/ ECs (2  105) in Matrigel and implanted subcutaneously into lal/
recipient mice for 10 days. A representative gross picture of tumor growth is
shown (n5).B, statistical analysis of tumorplugweight.C, statistical analysis
of tumorplugvolume.D, left panel, representativeH&E stainingof tumorplug
sections. Arrows indicate newly formedmicrovessels. Original magnification,
400. Scale bars 100 m. Right panel, statistical analysis of relative tumor
areas and quantification of vessel density by counting the number of vessels
per field. E, B16 melanoma or LLC cells (4  105) were mixed with lal/ or
lal/ ECs (4 105) and injected intravenously into lal/mice for 2 weeks.
Representative lungs and quantitative analysis of B16 melanoma colonies in
the lungs are shown (n 5). F, representative H&E staining of the lungs in E,
including statistical analysis of relative tumor areas. Original magnification,
200. Scale bars  200 m. For all experiments, data are expressed as
mean S.D. n 45. *, p 0.05; **, p 0.01.
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Tumor cells were treated with mitomycin C to eliminate the
potential effects of cell proliferation in these assays. As shown
in Fig. 2D, 24 h after co-culture with lal/ EC-CM, LLC cells
migrated more efficiently into the area of an artificial wound
compared with those treated with lal/ EC-CM. However, no
significant difference was observed when B16 melanoma
cells were treated with lal/ EC-CM. The discrepancy
between LLC and B16 cells means that cancer cells from
different origins have different features. Taken together,
these results suggested that lal/ ECs stimulated tumor
cell proliferation, migration, adhesion, and transendothelial
migration in vitro.
We previously reported that chemokines and cytokines
secreted by lal/ ECs are responsible for mediating myeloid
cell transendothelial migration (9). Here we further investi-
gated whether these cytokines/chemokines play a role in the
tumor-stimulating abilities of lal/ ECs. An ELISA confirmed
the elevated secretion of IL-6 and monocyte chemoattractant
protein 1 (MCP-1) by lal/ ECs (Fig. 2E), consistent with their
up-regulated mRNA levels, as we reported previously (9). To
examine whether IL-6 andMCP-1 secreted by lal/ ECs facil-
itated tumor cell proliferation, EC were treated with anti-IL-6
or anti-MCP-1 neutralizing antibodies. CM harvested after-
ward was used to treat tumor cells for 72 h. As shown in Fig. 2F,
compared with control IgG-treated EC-CM, LLC cell prolifer-
ation was decreased with anti-MCP-1 treated lal/ EC-CM,
whereas anti-IL-6–treated EC-CM had no effect on cancer cell
proliferation (B16 showed a decrease with no statistical differ-
ence). Combination of anti-IL-6 and anti-MCP-1 antibody–
treated lal/ EC-CM did not further block LLC cell prolifer-
ation. Therefore, MCP-1 was a primary factor responsible for
stimulating LLC cell proliferation. To exclude the potential
effect of neutralizing antibodies on tumor cell proliferation,
antibodies were directly added to tumor cell culture medium,
which had no effect on tumor cell proliferation.
To study whether IL-6 and MCP-1 secreted by lal/ ECs
facilitated tumor cell adhesion and transmigration, ECs were
treated with anti-IL-6 or anti-MCP-1 neutralizing antibodies.
As Fig. 2G shows, both B16 melanoma and LLC cells showed
decreased adhesion to lal/ ECs that were pretreated with
anti-IL-6 or anti-MCP-1 antibody or both. The results in Fig.
2H show that fewer LLC cells transmigrated through ECs that
were pretreated with anti-MCP-1 antibody or both antibodies
than through those treated with control IgG. Finally, their
effects on tumor cell migration were examined. Because there
was no significant difference in B16 melanoma cell migration
between lal/ and lal/ EC-CM (Fig. 2D), only LLC cells
were tested here. After co-culture with lal/ EC-CM that was
pretreated with anti-IL-6 or anti-MCP-1 antibodies or both,
LLC cells migrated less efficiently into the area of an artificial
wound compared with those co-cultured with control IgG.
Neutralizing antibodies alone had no direct effect on LLC
cell migration (Fig. 2I). Taken together, increased secretion
of IL-6 and MCP-1 by lal/ ECs contributed to enhanced
tumor cell proliferation, migration, adhesion, and transen-
dothelial migration.
LAL deficiency increased Rab7 GTPase expression in ECs
Rab7 GTPase is a key regulatory protein controlling biogen-
esis and trafficking of lysosomes. In lal/ mice, increased
Rab7 GTPase expression has been observed in MDSCs (14).
Similarly, Western blot and immunocytochemical staining
analyses detected an increased level of Rab7 GTPase in lal/
ECs (Fig. 3, A and B). Furthermore, immunofluorescence co-
staining demonstrated co-localization of the lysosomal marker
Figure2. lal/ECs stimulated tumor cell proliferation,migration, adhe-
sion, and transendothelialmigration in vitro.A, B16melanomaor LLC cells
(2 104) were co-cultured with CM of lal/ or lal/ ECs in vitro for 72 h for
tumor cell enumeration. B, CMFDA-labeled tumor cell (B16melanoma or LLC
cells, 1 104) adhesion to a lal/ or lal/ ECmonolayer. Total cell number
of five fields in each well was quantified using a fluorescence microscope. C,
CMFDA-labeled LLC transendothelial migration across the lal/ or lal/ EC
monolayers in the Transwell assay. LLC cells migrated to the lower chamber
were counted.D, tumor cell migration after lal/ or lal/ EC-CM treatment
by in vitro wound healing assay at 15 h in the presence of mitomycin C. E,
secretion of IL-6 and MCP-1 by ECs in the culture medium was measured by
ELISA. F, antibody neutralization against IL-6 and MCP-1 individually or in
combination in ECs; IgG was the control. The CM was harvested and used to
treat B16 melanoma or LLC cells (5  103) in vitro for 72 h for tumor cell
enumeration. To exclude the potential effects of neutralizing antibody on
tumor cells, neutralizing antibodies or control (C) IgG were added to tumor
cell culturemediumdirectly.G, CMFDA-labeled tumor cell (B16melanoma or
LLC cells, 1  104) adhesion to lal/ or lal/ EC monolayers that were
pretreated with neutralizing antibody against IL-6, MCP-1 individually or in
combination or control IgG. H, CMFDA-labeled LLC transendothelial migra-
tion across the lal/ or lal/ ECs monolayers that were pretreated with
neutralizing antibodies or control IgG. I, tumor cell migration after neutraliz-
ing antibody–pretreated EC-CM treatment was assessed by in vitro wound
healing assay in the presence of mitomycin C. For all experiments, data are
expressed as mean S.D. n 34. *, p 0.05; **, p 0.01.
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LAMP1 and Rab7 GTPase; lal/ ECs showed many more
LAMP1-positive lysosomes around the perinuclear region (Fig.
3C). The metabolic master regulator mTOR plays a key role in
controlling lal/ ECmetabolic reprogramming (9). Increased
expression and co-localization of Rab7 GTPase and mTOR on
the lysosomes of lal/ ECs were detected (Fig. 3C). These
results imply that Rab7 GTPase actively participates in lal/
EC tumorigenesis, perhaps through regulation of the mTOR
pathway.
Rab7 GTPase interacted withmTOR and influenced its
downstream signaling
Wehave recently reported that themTOR signaling pathway
is regulated by Rab7 GTPase in myeloid cells (17). To investi-
gate whether the same regulation occurs in lal/ ECs, siRNA
(a pool of three different sets) was used to effectively knock
down Rab7 GTPase expression in lal/ ECs, as confirmed by
immunofluorescence staining (Fig. 4A). Western blot analysis
showed that Rab7 GTPase siRNA knockdown not only effec-
tively reduced Rab7 GTPase protein expression by around 70%
but also down-regulated mTOR and downstream pS6 (phos-
pho-S6 ribosomal protein) levels in lal/ ECs (Fig. 4B). Three
individual Rab7 GTPase siRNAs were also tested separately,
which achieved the same results (supplemental Fig. 1). An
immunoprecipitation assay using anti-Rab7 GTPase antibody
showed increased mTOR immunoprecipitation intensity of
lal/ EC lysate compared with lal/ EC lysate (Fig. 4C).
These findings were further confirmed by GST pulldown assay
using purified recombinant Rab7 proteins (Fig. 4D, left panel).
After incubation with EC protein extracts, GST-Rab7 GTPase
fusion protein pulled down mTOR protein in both lal/ and
lal/ ECs, with stronger mTOR intensity in lal/ ECs (Fig.
4D, center and right panels). As a control, GST showed no pull-
down signal in both ECs. Therefore, Rab7 GTPase is physically
associated with mTOR with enhanced interaction in lal/
ECs. We have recently reported that, in myeloid cells, Rab7
GTPase interacts with the N-terminal heat repeat domain of
mTOR (17). This was confirmed in ECs by a GST–mTOR
N-terminal fusion fragment (M1A). AGST–mTORC-terminal
fusion fragment (M4)was used as a negative control. TheGST–
M1A mTOR fusion fragment showed a stronger interaction
with endogenous Rab7GTPase protein in lal/EC cell extract
than that of lal/ ECs, whereas the GST–M4 mTOR fusion
fragment showed no pulldown (Fig. 4F, right panel).
Figure 3. LAL deficiency increased Rab7GTPase expression and co-localizationwith LAMP1 andmTOR in ECs. A, left panel, representativeWestern blot
analysis of the Rab7 GTPase protein level in lal/ versus lal/ ECs. Right panel, statistical analyses of three independentWestern blot analyses. *, p 0.05. B,
immunocytochemical staining of Rab7GTPase in lal/ versus lal/ ECs. Originalmagnification,400. Scale bars 100m.C, immunofluorescence co-stain-
ing of the lysosomal marker LAMP1, Rab7 GTPase, and mTOR in lal/ versus lal/ ECs. Original magnification,600. Scale bars 20 m.
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Inhibition of Rab7 GTPase impaired lal/ EC permeability
andmigration and decreased reactive oxygen species
overproduction
To investigate whether increased Rab7 GTPase expression is
responsible for lal/ EC dysfunction, siRNAs were used to
knock downRab7GTPase expression in lal/ ECs. An in vitro
wound healing assay was performed to determine lal/ EC
migrating abilities. The results showed that migration toward
the scratchwas delayed in lal/ECswith Rab7GTPase siRNA
transfection at 15 h after creating the scratch (Fig. 5A), indicat-
ing that Rab7 GTPase inhibition impaired lal/ EC increased
migration.
ECs control transmigration of leukocytes or tumor cells from
the vasculature to inflammatory or metastatic sites. Next, EC
permeability was analyzed by Transwell assay. After ECs were
transfected with Rab7 GTPase or control siRNA for 48 h,
CMFDA-labeled lal/ bone marrow–derived Ly6G cells
were loaded on the ECmonolayer. Four hours later, the number
Figure 4. Rab7GTPase interactedwithmTOR and influencedmTORdownstream signaling. A, immunofluorescence staining of Rab7 GTPase in ECs after
Rab7 GTPase siRNA knockdown. Original magnification,600. Scale bars 10 m. C, control. B, Rab7 GTPase siRNA knockdown reduced mTOR, phosphory-
lated S6 and Rab7 GTPase protein levels in ECs by Western blot analysis. C, immunoprecipitation (IP) assay of Rab7 GTPase and mTOR interaction. EC lysates
were immunoprecipitated by control IgG (IgG) or anti-Rab7 GTPase antibody (Rab7) and detected by anti-mTOR antibody in Western blot analysis. Left panel,
a representative immunoprecipitationdetectedbyWesternblot analysis.Right panel, statistical analyses of three independent immunoprecipitation assays. IB,
immunoblot. D, GST pulldown assay of Rab7 GTPase and mTOR interaction. Left panel, the purity of recombinant GST and Rab7–GST fusion protein was
visualized by Coomassie Blue staining on SDS-PAGE. Center panel, lal/ and lal/ EC lysates were incubated with purified recombinant GST or Rab7–GST
fusion protein, pulled down with GST beads, and detected by anti-mTOR antibody in Western blot analysis. Right panel, statistical analyses of three indepen-
dent Rab7-GST pulldown assays.MW, molecular weight. E, schematic of themTOR domain structure (top) and PCR-generated GST–mTORM1A andM4 fusion
fragments (bottom). F, left panel, expression andpurification of two recombinantmTOR fragment GSTs. Top right panel, pulldownof endogenous Rab7GTPase
in lal/ or lal/ ECs by recombinant mTOR M1A–GST and mTOR M4–GST fusion fragments. Bottom right panel, statistical analyses of three independent
mTOR fragment GST pulldown assays. Onemicrogramof inputwas loaded on the gels for the pulldown and immunoprecipitation experiments. *, p 0.05; **,
p 0.01.
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of Ly6G cells in the lower chamber was significantly reduced
across lal/ ECs transfected with Rab7 GTPase siRNA com-
pared with those transfected with control siRNA (Fig. 5B), sug-
gesting that Rab7 GTPase inhibition reduced the permeability
of lal/ ECs. Rab7 GTPase inhibition did not affect lal/ EC
proliferation (Fig. 5C).
Reactive oxygen species (ROS) overproduction has been
observed in lal/ ECs and is a mechanism underlying lal/
EC dysfunctions that are mediated by mTOR overactivation
(9). To test whether Rab7 GTPase regulates ROS production in
lal/ ECs, the ROS level was measured by flow cytometry
analysis in ECs transfected with Rab7 GTPase or control
siRNA. As Fig. 5D shows, knocking down Rab7GTPase expres-
sion significantly reduced ROS production in lal/ ECs.
Inhibition of Rab7 GTPase impaired lal/ EC stimulation of
tumor growth andmetastasis in vivo and transendothelial
migration, proliferation, andmigration in vitro
Because lal/ECs stimulated tumor growth andmetastasis,
it would be intriguing to know the role of Rab7 GTPase in these
pathogenic functions. To study B16 melanoma growth, ECs
after Rab7 GTPase or control siRNA transfection were subcu-
taneously injected with B16 melanoma cells into the flank
region of lal/ recipient mice. Ten days post-injection,
mice injected with Rab7 GTPase siRNA–transfected lal/
ECs developed less tumor burden than those with control
siRNA–transfected lal/ ECs (Fig. 6A). We made similar
observations at other timepoints (7, 14, 17, 21, and 24 days; data
not shown). To study B16 melanoma invasion, ECs after Rab7
GTPase or control siRNA transfection were co-injected with
B16 melanoma cells into lal/ recipient mice intravenously.
Two weeks later, mice injected with Rab7 GTPase siRNA–
transfected lal/ ECs developed fewer melanoma metastatic
lesions in their lungs (Fig. 6B, top panel). Statistical analysis
revealed fewer melanoma colonies in the lungs of mice that
received Rab7 GTPase siRNA-transfected ECs than in those
that received control siRNA–transfected ECs (Fig. 6B, bottom
panel). This was further examined by an in vitro transendothe-
lialmigration study. ATranswell assay was performedwith ECs
transfected with Rab7 GTPase or control siRNA and cultured
in the upper chamber for 48 h. CMFDA-labeled LLC cells were
loaded on the EC monolayer. Fifteen hours later, LLC cells in
the lower chamber were significantly fewer across lal/ ECs
transfected with Rab7 GTPase siRNA than those across lal/
ECs transfected with control siRNA (Fig. 6C). These results
suggest that Rab7GTPase inhibition reduced lal/ECperme-
ability, reducing tumor cell transendothelial migration and
invasion. In addition, the effects of Rab7GTPase knockdown in
ECs on tumor cell proliferation and migration were investi-
Figure 5. Inhibition of Rab7GTPase impaired lal/ EC permeability and
migration and decreased ROS overproduction. A, ECmigration after Rab7
GTPase siRNA knockdownwas assessed by an in vitrowound healing assay in
the presence of mitomycin C. C, control. B, MDSC transendothelial migration
was determined after Rab7GTPase siRNA knockdown in ECs for 48 h. CMFDA-
labeled bone marrow–derived MDSCs were added to the siRNA-transfected
ECmonolayers. Four hours later, MDSCs in the lower chamber were counted.
C, EC proliferation after Rab7 GTPase siRNA knockdown.D, statistical analysis
of mean fluorescent intensity (MFI) of the ROS level in ECs after Rab7 GTPase
siRNA knockdown by flow cytometry. For all experiments, scrambled siRNA
transfection served as a control, and data are expressed as mean S.D. n
45. *, p 0.05; **p 0.01. Figure 6. Inhibition of Rab7 GTPase impaired lal
/ EC stimulation of
tumor growth and metastasis in vivo and transendothelial migration,
proliferation, and migration in vitro. A, ECs (2 105) with Rab7 GTPase or
control siRNA knockdownweremixedwith B16melanoma cells (1 105) and
injected subcutaneously into the flank region of lal/ mice. Quantitative
analysis of tumor volume 10 days post-injection was statistically analyzed. B,
ECs (4 105)with Rab7GTPase or control siRNAknockdownweremixedwith
B16 melanoma cells (4 105) and co-injected intravenously into lal/mice
for 2 weeks. Representative lungs are shown. Quantitative analysis of mela-
noma colonies in the lungs of lal/ recipientmice was statistically analyzed.
C, control. C, LLC cell transendothelial migration was determined after Rab7
GTPase siRNA knockdown in ECs. D, B16 melanoma or LLC cell (5  103)
proliferation was examined with CM of ECs transfected with Rab7 GTPase or
control siRNA. E, tumor cell migrationwas assessed by in vitrowound healing
assay after treatmentwith CMof ECs transfectedwith Rab7GTPase or control
siRNA. F, ELISA of secreted IL-6 andMCP-1 by ECswith Rab7GTPase or control
siRNAknockdown. In all experiments, scrambled siRNA transfection served as
a control, and data are expressed asmean S.D. n 48. *, p 0.05; **, p
0.01.
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gated. ECs were transfected with Rab7 GTPase or control
siRNA for 24 h, and the transfectionmediumwas then replaced
with DMEMwith 5% FBS. Two days later, CMwas harvested to
treat tumor cells. As shown in Fig. 6D, compared with CM
harvested from control siRNA–transfected lal/ ECs, both
B16 melanoma and LLC cell proliferation was significantly
inhibitedwithCMfromRab7GTPase siRNA–transfected lal/
ECs. An in vitro tumor cell migration assay showed that LLC
cells migrated less efficiently into the wound area after co-cul-
ture with CM from Rab7 GTPase siRNA–transfected lal/
ECs than those co-cultured with CM from control siRNA–
transfected lal/ ECs (Fig. 6E).
We have shown that increased secretion of IL-6 and MCP-1
by lal/ECs contributed to enhanced tumor cell proliferation,
migration, and transendothelial migration (Fig. 2, E–I). To
investigate whether Rab7 GTPase affects lal/ EC tumor-
stimulating abilities by regulating secretion of chemokines/cy-
tokines, the levels of IL-6 andMCP-1were examined after Rab7
GTPase knockdown by ELISA. The results showed that knock-
down of Rab7 GTPase reversed the elevated secretion of IL-6
and MCP-1 in lal/ ECs (Fig. 6F). Taken together, Rab7
GTPase knockdown reduced lal/ EC stimulation of tumor
cell transendothelial migration, proliferation, and migration
through down-regulating cytokine/chemokine secretion.
Inhibition of Rab7 GTPase increased tube formation and
tumor binding to ECs
Rab7 GTPase did not always overlap with mTOR in regulat-
ing lal/ EC functions. Flow cytometry analysis showed that
Rab7 GTPase knockdown by siRNA transfection increased the
expression level of VEGFR2 in lal/ECs (Fig. 7A). As reported
before, VEGFR2mediates impairment of lal/ EC tube-form-
ing capability (9). Indeed, Rab7 GTPase knockdown reversed
the tube-forming impairment of lal/ ECs and formed more
complete tube networks than control siRNA (Fig. 7B). In a sep-
arate study, Rab7 GTPase knockdown in lal/ ECs signifi-
cantly increased B16 melanoma and LLC cell binding to lal/
ECs than those transfected with control siRNA (Fig. 7C), which
was associated with elevated expression of E-selectin and P-se-
lectin in lal/ ECs with Rab7 GTPase siRNA transfection
comparedwith thosewith control siRNA transfection (Fig. 7D).
Discussion
The tumor environment contains various stromal cells that
nurture tumor initiation, growth, andmetastasis. ECs are a very
important component of stromal cells in the tumor environ-
ment (1) and serve as a barrier to control penetration of tumor
cells and tumor-stimulating inflammatory cells into organs (9).
ECs not only regulate anti-tumor immunity (i.e.myeloid and T
cell functions) but also directly influence tumor proliferation,
growth, and metastasis through paracrine and juxtacrine
mechanisms (18, 19). To control tumorigenesis, ECs are a crit-
ical target for cancer therapy. Understanding the molecular
mechanisms and new pathways that govern EC functions can
greatly facilitate new drug discovery.
A dysregulated metabolism has been reported to lead to EC
dysfunction (7, 8). We have strong evidence showing that a
neutral lipid metabolism controlled by LAL plays a critical role
in EC anti-tumor functions (9). LAL deficiency significantly
changes EC functions toward tumor promotion. In this study,
lal/ ECs facilitated in vivo tumor angiogenesis, growth, and
metastasis (Fig. 1) and directly stimulated in vitro tumor prolif-
eration, migration, adhesion, and transendothelial migration in
co-culture with B16 melanoma or LLC cells (Fig. 2). Lal/ EC
tumorigenic functions are largely mediated by the lysosome-
anchored metabolic regulator mTOR, as we reported previ-
ously (9). In lal/ myeloid cells, in the absence of fatty acid
metabolism, cells have to overactivate the glycolytic pathway to
produce ATP through oxidative phosphorylation (14, 20),
which, however, can cause mitochondrial impairment and lead
to increased ROS production (21). ROS overproduction was
observed in lal/ ECs, and neutralization of ROS by antioxi-
dant N-acetyl-L-cysteine reversed lal/ EC dysfunction (9).
Inhibition of themTORpathway reversed ROSoverproduction
in lal/ ECs and rescued EC dysfunction (9).
Because membrane trafficking causes mTOR shuttling to
lysosomes and regulates mTOR signaling, identification of fac-
tors that regulate lysosomal genesis and distributionwill greatly
Figure 7. Inhibitionof Rab7GTPase increased tube formation and tumor
binding to lal/ECs.A, flowcytometry analysis of VEGFR2expression in ECs
after Rab7 GTPase siRNA knockdown. C, control. B, EC in vitro Matrigel tube
formationwas assessed after Rab7GTPase siRNA knockdown. Statistical anal-
ysis of cumulative tube lengths 6 h after EC seeding on Matrigel is shown. C,
CMFDA-labeled tumor cell (B16 melanoma or LLC cells, 1 104) adhesion to
ECs after Rab7 GTPase siRNA knockdown. Five fields in each well were quan-
tified using a fluorescence microscope. D, flow cytometry analysis of expres-
sion of E-selectin and P-selectin in ECs after Rab7 GTPase siRNA knockdown.
In all experiments, scrambled siRNA transfection served as a control, and data
are expressed as mean S.D. n 45. *, p 0.05; **, p 0.01.
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benefit our understanding to control unwanted metabolic
reprogramming in lal/ ECs and, therefore, to control tumor
angiogenesis, migration, and penetration. In this report, we
have identified that Rab7 GTPase, a lysosomal protein control-
ling lysosomal genesis and trafficking, was up-regulated in
lal/ ECs by Western blot assay (Fig. 3A) and immunocyto-
chemical staining (Fig. 3B). Immunofluorescence co-staining
showed enhanced lysosomal genesis in association with in-
creased expression of Rab7 GTPase and mTOR in lal/ ECs.
Interestingly and importantly, co-localization of Rab7 GTPase
withmTOR on lysosomes has been observed (Fig. 3C), suggest-
ing that the lysosome serves as a major warehouse for mTOR
and Rab7 GTPase to interact. In this study, Rab7 GTPase
knockdown resulted in down-regulation ofmTORdownstream
signaling in ECs (Fig. 4B), indicating that lysosome-anchored
Rab7 GTPase regulates mTOR signaling in ECs. Physical inter-
action betweenRab7GTPase andmTOR inECextract has been
identified. Rab7 GTPase interacted with mTOR through its
N-terminal heat repeat domain, and LAL deficiency leads to
enhanced interaction between these two proteins in ECs (Fig. 4,
C–F). This observation is consistent with our recent observa-
tion in myeloid cells (17). Rab7 GTPase is a late endosome/
lysosome-associated small GTPase, participating in multiple
regulatory mechanisms in endosomal sorting, biogenesis of
lysosomes, and phagocytosis. Its mutations or dysfunctions
result in traffic disorders that cause various diseases, such as
cancer, lipid metabolism disease, and neuropathy (16, 22, 23).
The Rab7 small GTPase is an early-induced melanoma driver
whose levels can be up-regulated in melanoma as part of a lys-
osome-associated signature (24).
Because Rab7 GTPase andmTORwere co-localized on lyso-
somes of lal/ ECs and Rab7 physically interacts with mTOR,
we speculate that Rab7 GTPase is involved in mTOR-mediated
cellular and pathogenic phenotypes, as we reported previously
(9). At the cellular level, Rab7 GTPase inhibition decreased
ROS overproduction in lal/ ECs (Fig. 5D), which was
increased by mTOR overactivation. Several other mTOR-me-
diated cellular phenotypes were investigated by blocking Rab7
GTPase in lal/ ECs. We have shown that LAL deficiency
increases ECs migration (9). Knocking down Rab7 GTPase in
lal/ ECs impaired enhanced EC migration (Fig. 5A). ECs
serve as a barrier controlling the penetration of leukocytes into
organs. An inflammatory status caused by LAL deficiency
increases ECpermeability to allow tumor cells and tumor-stim-
ulating immune cells transmigrating through the EC mono-
layer and accumulating in distal organs of lal/ mice (9, 25).
Rab7 GTPase knockdown decreased LLC cell and Ly6G cell
transmigration across the lal/ EC monolayer (Figs. 5B and
6C). At the pathogenic level, lal/ ECs stimulated in vivo
tumor angiogenesis, growth, and metastasis (Fig. 1). Rab7
GTPase inhibition reduced not only in vivo tumor growth and
metastasis (Fig. 6, A and B) but also in vitro tumor cell prolifer-
ation and migration (Fig. 6, D and E). For the in vivo experi-
ments, the difference in tumor growth could be due to the ini-
tial differences in ECs transfectedwith Rab7 or control siRNAs.
In addition, transfected Rab7 siRNAs can cause profound bio-
logical effects, including irreversible genetic and epigenetic
changes. Rab7 siRNA transfection also decreased transendo-
thelial migration of Ly6Gmyeloid cells (Fig. 5B), which plays
an important role in tumor progression. Therefore, although
cells could not retain siRNAs for a long time, a difference in
tumor growth has been observed. Taken together, these obser-
vations collectively indicate that the lysosomal trafficking-con-
trolling Rab7 GTPase regulates the LAL–mTOR axis in ECs,
which contributes greatly to tumorigenesis.
Besides mTOR-mediated cellular and pathogenic pheno-
types, the paracrine mechanism may contribute to lal/ EC
tumorigenic effects, as evidenced by increased secretion of IL-6
and MCP-1 by lal/ ECs, and these tumorigenic effects were
reversed by anti-IL-6 and/or anti-MCP-1 neutralizing antibod-
ies (Fig. 2, E–I). Inhibition of Rab7 GTPase reversed the
elevated secretion of IL-6 and MCP-1 in lal/ ECs (Fig. 6F),
suggesting that Rab7 GTPase could regulate lal/ EC
tumorigenic effects through modulating cytokine/chemokine
secretion.
Although most functions of Rab7 overlap with mTOR, there
are a few cellular events promoted by mTOR that were
enhanced further by Rab7 GTPase inhibition in lal/ ECs.
mTOR inhibition has been reported to decrease EC tube-form-
ing capability (26). Rab7GTPase inhibition increased lal/EC
tube-forming capability in vitro (Fig. 7B), in association with
up-regulated expression of VEGFR2 and adhesion molecules
(E-selectin and P-selectin) (Fig. 7,A andD). Rab7 GTPase inhi-
bition also increased B16 melanoma and LLC cell binding abil-
ity to lal/ ECs (Fig. 7C). These discrepancies suggest that, in
addition to interaction with mTOR, Rab7 GTPase may influ-
ence EC functions by interacting with mTOR-independent
pathways. Nevertheless, the overall outcome demonstrated
that tumor growth and metastasis were reduced with Rab7
GTPase inhibition of lal/ ECs, as shown in Fig. 6,A and B. In
conclusion, Rab7 GTPase is a crucial lysosomal component
that regulates LAL-controlled neutral lipid metabolism in ECs,
actively participates in the regulation of tumor proliferation,
progression, and metastasis, and serves as a therapeutic target
for cancer treatment.
Experimental procedures
Animals and cell lines
lal/ and lal/mice of the FVB/N background were bred
in-house. All scientific protocols involving the use of animals
were approved by the Institutional Animal Care and Use Com-
mittee of Indiana University School of Medicine and followed
guidelines established by the Panel on Euthanasia of the Amer-
ican Veterinary Medical Association. Animals were housed
under Institutional Animal Care and Use Committee–ap-
proved conditions in a secured animal facility at Indiana Uni-
versity School ofMedicine. Themurine B16melanoma cell line
and LLC cell line (ATCC, Manassas, VA) were cultured in
DMEM supplemented with 10% FBS (Gibco).
Isolation and in vitro culture of pulmonary ECs
ECs were isolated from lungs and cultured in vitro as we
described previously (9).
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In vivoMatrigel plug assay with ECs and tumor cells
This assay was performed according to established methods
with minor modifications (9, 27). ECs and tumor cells were
collected separately. After washing with PBS, 2 105 ECs were
mixed with 1  105 B16 melanoma or LLC cells in 500 l of
Matrigel Basement Membrane Matrix (BD Biosciences). The
cell–Matrigel mixture was then injected subcutaneously into
the abdomen of 3-month-old lal/ mice. After 10 days, the
mice were sacrificed, and plugs were harvested from under-
neath the skin. The plugs were fixed, embedded, sectioned,
stained with H&E, and examined using microscopy.
Mouse tumor growth andmetastasis models
The tumor growth and metastasis models have been
described recently (27, 28). A pilot study has been performed to
determine the best ratio between ECs and tumor cells. To test
the tumor growth potential, 4  105 ECs and 2  105 B16
melanoma or LLC cells were mixed, centrifuged, resuspended
in 100 l of PBS, and then injected subcutaneously into the
flank region of 3-month-old lal/ recipient mice. Tumor vol-
ume (length width2 /6) was monitored twice every week
for 4 weeks. To test the metastasis potential, 4  105 ECs and
4  105 B16 melanoma or LLC cells were mixed, centrifuged,
resuspended in 200 l of PBS, and then injected intravenously
into 3-month-old lal/ mice. Two weeks after the injection,
the mice were sacrificed, and the lungs were inflated with 4%
paraformaldehyde for examination of metastasis.
In vitro conditionedmedium treatment
To collect the CM of ECs, cells were cultured until 90% con-
fluent. The culture medium was replaced with 2 ml of DMEM
with 5% FBS in each well of 6-well plates. After 24 h, the
medium was collected and centrifuged to remove cell debris.
For the neutralization study, before harvesting the medium,
ECs were pretreated with 10 g/ml neutralizing antibody
against IL-6 or MCP-1 or control IgG for 1 h, and CM was
collected afterward. For the siRNAknockdown study, ECswere
transfected with Rab7 GTPase or control siRNA for 24 h. The
transfection medium was then replaced with DMEM with 5%
FBS. Two days later, CM was harvested for further study.
To determine the effect of EC-CM on tumor cell prolifera-
tion, B16melanoma or LLC cells were seeded at a density of 2
104 cells/well into a 24-well plate. After cells attached to the
plates, 500 l of CM harvested from lal/ or lal/ ECs was
added to eachwell. Seventy-twohours later, B16melanoma and
LLC cells were counted. For the neutralization and siRNA
knockdown study, 5  103 B16 melanoma or LLC cells were
seeded into a 96-well plate, and 200l of CMwas added to each
well. To exclude the potential effect of neutralizing antibodies
on tumor cell proliferation, antibodies were directly added to
tumor cell culture medium as a control.
To analyze the effect of EC-CM on tumor cell migration, in
vitro wound healing assays were performed as described previ-
ously (29). Briefly, B16 melanoma or LLC cells were seeded at a
density of 1.5 105 cells/well into a 24-well plate and incubated
overnight to form a confluentmonolayer. A scratchwas created
by scraping the cell monolayer in a straight line with a p200
pipette tip. After washing three times with PBS, the medium
was changed to 500 l of CM harvested from lal/ or lal/
ECs and 5g/mlmitomycinC (Sigma-Aldrich). Cells were kept
in culture at 37 °C, 5% CO2. Images were taken 0 and 15 h after
creating the scratch.Migrationwas estimated bymeasuring the
distances from one side of the scratch to the other side using
NIS Elements imaging software (Nikon, Melville, NY). To
exclude the potential effect of neutralizing antibodies on tumor
cell migration, antibodies were directly added to tumor cell
culture medium as a control.
Tumor cell binding assay
The tumor cell binding assay was performed as described
previously with minor modifications (30). ECs were plated in
24-well plates and incubated until they formed a uniform
monolayer. Tumor cells (B16 melanoma or LLC cells) were
prelabeled with CellTrackerTMGreenCMFDA (Invitrogen) for
30 min at 37 °C. Labeled tumor cells (1 104) were then added
to the EC monolayer and incubated for 3 h at 37 °C. At the end
of incubation, cells were gently washed, and the binding of
tumor cells to ECs was quantified under five fields in each well
using a fluorescence microscope (Nikon). For the neutraliza-
tion study, ECs were pretreated with 10 g/ml neutralizing
antibody against IL-6 or MCP-1 or control IgG for 1 h.
Transwell assay
Tumor cell or MDSC transendothelial migration was deter-
mined by Transwell assay as we reported previously, with
minor modifications (9, 31). Briefly, ECs were grown on Tran-
swells until they were confluent. CMFDA-labeled LLC cells
(2 104 cells in 250 l of medium) or MDSCs (1 104 cells in
250l of medium) were added to the ECmonolayer. For tumor
cell transmigration, hepatocyte growth factor was added to the
lower chamber as a chemoattractant. Tumor cells were allowed
to transmigrate for 15 h. The LLC cells that crossed the ECs
were counted under five randommicroscopic fields (4, 32). For
MDSCs, after 4 h, their transendothelial migration was deter-
mined by counting their numbers in the lower chamber. For the
neutralization study, ECs were pretreated with 10 g/ml neu-
tralizing antibody against IL-6 orMCP-1 or control IgG for 1 h.
ELISA
The expression levels of IL-6 and MCP-1 in EC-CM were
measured using ELISA kits (BD Biosciences) according to the
instructions of the manufacturer.
Western blot analysis
Western blot analysis was performed as described previously
(9, 27) with antibodies against Rab7 GTPase (rabbit monoclo-
nal antibodies, 1:1000, Cell Signaling Technology, Beverly,
MA).
Immunofluorescence staining
ECs were fixed for 15 min in 4% paraformaldehyde and per-
meabilized for 10 min in 0.02% Triton X-100. After washing,
ECs were blocked with 1% BSA in PBST (PBS and 0.1% Tween
20) for 1 h. Cells were incubated with rabbit anti-Rab7 GTPase
antibodies (1:500) (Cell Signaling Technology), rat anti-lyso-
somal associate membrane protein 1 (LAMP1) antibodies
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(1:500, Santa Cruz Biotechnology, Santa Cruz, CA), mouse
anti-mTORantibodies (1:500), or rabbit anti-mTORantibodies
(1:500, Cell Signaling Technology) at 4 °C overnight. The fol-
lowing day, cells were incubated with fluorescence-conjugated
secondary antibody for 1 h. Images were examined under a
Nikon fluorescence microscope.
Small interfering RNA transfection
Before transfection, ECs were seeded into 6-well plates at a
density of 2.5  105 cells/well and incubated overnight. For
siRNA-mediated gene knockdown, 50 nmol/liter Rab7 siRNA
SMARTpool or control siRNA (Dharmacon, Chicago, IL) was
transfected into cells with DharmaFECT Transfection Reagent
IV (Dharmacon) according to the protocol of themanufacturer.
After 72 h of transfection, cells were harvested for further
analysis.
Three sets of Rab7 siRNAswere designed and synthesized by
Integrated DNA Technologies using Custom Dicer-Substrate
siRNA software: Rab7 siRNA1, 5	rArCrArGrGrArArArCrAr-
GrArArGrUrGrGrArArCrUrGrUAC (sense) and 5	rGrUrAr-
CrArGrUrUrCrCrArCrUrUrCrUrGrUrUrUrCrCrUrGrU-
rUrU (antisense); Rab7 siRNA2, 5	rGrUrUrGrUrGrUrUrGrG-
rGrArArArCrArArGrArUrUrGrACmC (sense) and 5	rGrGr-
UrCrArArUrCrUrUrGrUrUrUrCrCrCrArArCrArCrArArC-
rArA (antisense); Rab7 siRNA3, 5	rGrGrArArGrArArArGrU-
rGrUrUrGrCrUrGrArArGrGrUrCAT (sense) and 5	rArUrGr-
ArCrCrUrUrCrArGrCrArArCrArCrUrUrUrCrUrUrCrC-
rUrA (antisense).
Purification of recombinant Rab7 GTPase andmTOR
truncated fusion proteins
Recombinant Rab7 GTPase and mTOR truncated fusion
proteins were purified as we described previously (17).
Immunoprecipitation assay
The immunoprecipitation assay was performed as we
described previously (17). Proteins associated with Rab7
GTPase protein were detected by Western blot analysis using
anti-mTOR antibody (Cell Signaling Technology). One micro-
gram of “input” was loaded on the gels. Quantification of pro-
tein levels was determined by measuring band intensity using
Image Lab 4.1 software (Bio-Rad) and calculating the ratio of
the protein of interest to an internal loading control.
GST pulldown assay
The pulldown assay was performed as we described previ-
ously to evaluate the interaction between Rab7 GTPase and
mTOR truncated fragments (GST–mTOR–M1A and GST–
mTOR–M4) (17). Proteins associated with the mTOR trun-
cated fragment fusion protein were detected by Western blot
analysis using anti-Rab7 GTPase antibody (Cell Signaling
Technology). One microgram of input was loaded on the gels.
In vitro wound healing assay
The in vitro wound healing assay was performed to analyze
EC migration as described previously (9, 29).
Tube formation assay
The in vitro angiogenic activity of ECs was determined by
Matrigel tube formation assay, as we described previously (9,
33). Tube formation was defined as a tube-like structure exhib-
iting a length four times its width (34).
Flow cytometry analysis
ECs after siRNA transfection were harvested and washed
with PBS. To detect the VEGFR-2 expression level, cells were
incubated with allophycocyanin (APC)-conjugated anti-
mouse VEGFR-2 antibody (eBioscience, San Diego, CA). To
examine the effects of Rab7 siRNA knockdown on the
expression of adhesion molecules, cells were incubated
with phycoerythrin-conjugated anti-mouse E-selectin and
phycoerythrin-conjugated anti-mouse P-selectin antibodies
(eBioscience), respectively. For flow cytometry analysis,
10,000 cells were acquired and scored using a LSRII
machine (BD Biosciences). Data were processed using the
CellQuest software program (BD Biosciences).
ROSmeasurement
The ROS level in ECs was measured by flow cytometry as we
described previously (9).
Statistics
Data were expressed as mean  S.D. Differences between
two treatment groups were compared by Student’s t test.When
more than two groupswere compared, one-way analysis of vari-
ance with post hoc Newman–Keul multiple comparisons test
was used. Results were considered statistically significant when
p 0.05. All analyses were performedwithGraphPad Prism 5.0
(GraphPad, San Diego, CA).
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